Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT03359759 Recruiting - Breast Cancer Clinical Trials

Evaluation of Efficiency in Cancerology of New Technologies as Telemedicine and Conected Objects (e-DomSanté)

e-DomSanté
Start date: June 2016
Phase: N/A
Study type: Observational

Observational study about patients treated for a metastasis breast cancer who live far from their comprehensive cancer center and followed by telemedicine, connected wtaches and patient-reported symptom monitoring.

NCT ID: NCT03358511 Recruiting - Breast Cancer Clinical Trials

Engineering Gut Microbiome to Target Breast Cancer

Start date: October 11, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if using probiotics will help the body's immune system react to breast cancer. New studies showed that diverse species of bacteria inside the bowel might help improve immune system, particularly the ability of immune system to recognize cancer. This study will investigate how probiotics will affect the subjects' immune system on breast cancer.

NCT ID: NCT03357744 Completed - Breast Cancer Clinical Trials

The Distress-barometer: Face-to-face Interviews or Written Self-report Questionnaires?

Start date: June 2016
Phase: N/A
Study type: Observational [Patient Registry]

Breast cancer is the most prevalent cancer among women worldwide [1]. 5 years after diagnosis, up to 87% survives. A substantial group of these survivors report reduced physical, psycho social and cognitive functioning. Therefore, it is increasingly important to screen for distress, both during and after treatment. The Distress Barometer (DB) is a valid, short screening instrument, used to detect elevated levels of distress in patients with cancer. It can be used either in a self-report questionnaire or in an interview format. Although the DB is used in different ways, it remains unclear whether both assessment methods would generate similar results, and which format is most suitable to represent the actual level of distress. Existing literature on the DB lacks a systematic description of the relationship between the method of assessment and the patients' responses. This study questions whether the written and interview variants of the DB reveal different results in the same patients with breast cancer.

NCT ID: NCT03357120 Recruiting - Breast Cancer Clinical Trials

Circulating Tumor DNA After Neoadjuvant Chemotherapy

ALIENOR
Start date: October 6, 2017
Phase: N/A
Study type: Interventional

Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological response.

NCT ID: NCT03356860 Recruiting - Breast Cancer Clinical Trials

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

B-IMMUNE
Start date: April 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study has a phase Ib and a phase II part. - The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer. - The phase II aims to explore the efficacy of durvalumab in combination with a dose-dense EC regimen in a neoadjuvant setting for early breast cancer.

NCT ID: NCT03355261 Recruiting - Breast Cancer Clinical Trials

Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)

Start date: May 1, 2014
Phase: N/A
Study type: Interventional

To investigate the regression model of positive nodes after neoadjuvant chemotherapy (NAC) by injecting and tracing carbon nanoparticles (CNs) in fusion node prior to NAC in patients with breast cancer.

NCT ID: NCT03354611 Not yet recruiting - Breast Cancer Clinical Trials

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Start date: December 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Up to one hundred (100) female patients will be enrolled and consented to participate in the study. These women will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammography and before breast biopsy if biopsy is needed. The final diagnostic workup outcome of these enrolled patients needs to include at least 30 confirmed cancers cases.

NCT ID: NCT03351348 Recruiting - Breast Cancer Clinical Trials

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Start date: November 16, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare using bupivacaine (a numbing medicine) along with the usual medications for post-operative pain control to using the usual medications for post-operative pain control alone. The addition of bupivacaine to the usual pain medications could better manage pain immediately after surgery. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.

NCT ID: NCT03350854 Completed - Breast Cancer Clinical Trials

Improving Decision Role Concordance in Newly Diagnosed Breast Cancer Patients

Start date: March 7, 2016
Phase: N/A
Study type: Interventional

The goal of this project is to test the effects of the Patient Preference Scale as the basis for a clinical intervention for role negotiation in breast cancer surgery decisions and the Patient Perception Scale to measure role concordance. The investigators hypothesize that better role concordance will be achieved with a simple provider-based intervention. In the first half of the study, providers will be blind to the patient's preferred role. In the second half, providers will be made aware of the preferred role prior to the encounter and will have a brief conversation with the patient about their desired role in the decision making process.

NCT ID: NCT03349177 Not yet recruiting - Breast Cancer Clinical Trials

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Start date: November 27, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Neoadjuvant chemotherapy (NAC) has become the standard therapy for both locally advanced and early-stage breast cancer in recent years for the improvement breast conserving surgery rate and the evaluation of treatment response in vivo. Pathological complete response (pCR) is an independent prognostic factor irrespective of breast cancer intrinsic subtypes after NAC. The trial is designed to compare effectiveness between anthracycline and/or taxane as neoadjuvant chemotherapy for operable advanced breast cancer in different molecular typing. In this trial the investigators will randomly assign 200 primary breast cancer patients to receive six cycles of fluorourcil, epirubicin,and cyclophosphamide(FEC), or four cycles of epirubicin and cyclophosphamide (EC) followed by four cycles of docetaxel(T), or six cycles of docetaxel and cyclophosphamide (TC). Trasuzumab was recommended combining docetaxel to patients if HER-2 positive.The effectiveness of therapy will be estimated after every two cycles of neoadjuvant chemotherapy. Surgery will be performed after completing designated full cycles of neoadjuvant chemotherapy. The primary endpoint is to assess pathologic complete response (pCR, ypT0/is ypN0) rate in different regiments. The secondary endpoint is to assess the relationship between pCR rate with molecular typing in different regiments, so that the investigators could optimize neoadjuvant chemotherapy regiment according to molecular typing.